Prestige Consumer reports FY26 adj EPS $4.38; acquires LaCorium Health for $150M

Prestige Consumer Healthcare Inc.

FY26 revenue $1,088.7M (-4.3% YoY); adjusted diluted EPS $4.38 vs $4.52 prior year.
Q4 revenue $281.6M (-5% YoY); adjusted diluted EPS $1.23 vs $1.32.
Acquiring LaCorium Health (Australian therapeutic skincare) for ~$150M cash; expected close Q2 FY27.
LaCorium TTM revenue ~$40M; expected ~$12M EBITDA with synergies.
FY27 outlook: organic revenue growth 1-3%, adj EPS $4.42-$4.51, FCF $250M+.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.